Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

7.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.0K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.1K
Lipid Catabolism01:25

Lipid Catabolism

1.5K
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
1.5K
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

32
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
32
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

53
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
53
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

36
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
36

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer.

Cell death & diseaseยท2026
Same author

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS<sup>G12D</sup>-driven non-small cell lung cancer.

Molecular cancerยท2024
Same author

Rising hospital admissions for alcohol-related cirrhosis and the impact of sex and comorbidity - a data linkage study.

Public healthยท2024
Same author

A discrete choice experiment to elicit preferences for a chronic disease screening programme in Queensland, Australia.

Public healthยท2024
Same author

Combined positron emission tomography and contrast enhanced CT (PET/CeCT) is a feasible single investigation in the staging of oesophagogastric cancers: single-centre pilot study experience during the COVID-19 pandemic.

Annals of the Royal College of Surgeons of Englandยท2023
Same author

Medizinische Klinik, Intensivmedizin und Notfallmedizinยท2017
Same journal

How important is fiber in the Crohn's disease story?

Gastroenterologyยท2026
Same journal

Reply to "Critical Appraisal of the Integrin ฮฑV-YAP-CTGF Axis in Congestive Hepatopathy".

Gastroenterologyยท2026
Same journal

Critical Appraisal of the Integrin ฮฑV-YAP-CTGF Axis in Congestive Hepatopathy.

Gastroenterologyยท2026
Same journal

A High-Risk Impaction: To Scope or to Stent First?

Gastroenterologyยท2026
Same journal

Epithelial FOXP3 orchestrates O-glycosylated IL-6 secretion to drive pancreatic fibrocarcinogenesis.

Gastroenterologyยท2026
Same journal

Reply to "Methodological Considerations on Neonatal Metabolomics and Future Inflammatory Bowel Disease".

Gastroenterologyยท2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.5K

Steatohepatitis associated with limb lipodystrophy.

E E Powell1, J Searle, R Mortimer

  • 1Department of Medicine, University of Queensland, Brisbane, Australia.

Gastroenterology
|October 1, 1989
PubMed
Summary
This summary is machine-generated.

This study highlights a potential link between acquired partial lipodystrophy and steatohepatitis, a condition not previously well-documented. Researchers suggest a shared underlying mechanism may connect lipodystrophy, nonalcoholic steatohepatitis, and alcoholic liver disease.

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

Related Experiment Videos

Last Updated: May 6, 2026

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.5K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

Area of Science:

  • Hepatology
  • Metabolic Disorders
  • Endocrinology

Background:

  • Steatohepatitis, encompassing both nonalcoholic and alcoholic forms, represents a significant liver pathology.
  • Lipodystrophies are a group of rare genetic or acquired conditions characterized by the loss of adipose tissue.
  • Acquired partial lipodystrophy (APL) is a rare subtype affecting specific body areas.

Observation:

  • The study observed two patients with steatohepatitis who also presented with acquired partial lipodystrophy.
  • This co-occurrence has not been extensively documented in existing medical literature.

Findings:

  • A potential association between acquired partial lipodystrophy and steatohepatitis is identified.
  • The findings suggest that these conditions might share common pathophysiological pathways.

Implications:

  • Further research is warranted to elucidate the shared mechanisms between lipodystrophy and various forms of steatohepatitis.
  • Understanding this association could lead to novel diagnostic or therapeutic strategies for patients with these overlapping conditions.